MC

717

+0.35%↑

ALV

259.9

+0.08%↑

SAF

202.9

-0.2%↓

BBVA

9.178

-1.71%↓

BN

58.56

+1.91%↑

MC

717

+0.35%↑

ALV

259.9

+0.08%↑

SAF

202.9

-0.2%↓

BBVA

9.178

-1.71%↓

BN

58.56

+1.91%↑

MC

717

+0.35%↑

ALV

259.9

+0.08%↑

SAF

202.9

-0.2%↓

BBVA

9.178

-1.71%↓

BN

58.56

+1.91%↑

MC

717

+0.35%↑

ALV

259.9

+0.08%↑

SAF

202.9

-0.2%↓

BBVA

9.178

-1.71%↓

BN

58.56

+1.91%↑

MC

717

+0.35%↑

ALV

259.9

+0.08%↑

SAF

202.9

-0.2%↓

BBVA

9.178

-1.71%↓

BN

58.56

+1.91%↑

Search

Bayer AG

Closed

Sector Finance

26.055 0.04

Overview

Share price change

24h

Current

Min

26

Max

26.105

Key metrics

By Trading Economics

Income

663M

2B

Sales

1.9B

14B

P/E

Sector Avg

30.837

24.864

EPS

2.82

Dividend yield

4.737

Profit margin

14.524

EBITDA

1.3B

4.4B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+17.31 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.74%

4.45%

Next Earnings

6 sie 2024

Market Stats

By TradingEconomics

Market Cap

-1.5B

27B

Previous open

26.02

Previous close

26.055

News Sentiment

By Acuity

54%

46%

360 / 457 Ranking in Finance

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Bayer AG Chart

Related News

14 maj 2024, 13:21 UTC

Earnings

Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update

14 maj 2024, 06:13 UTC

Earnings

Bayer Net Profit Falls on Lower Sales, Currency Headwinds

2 maj 2024, 11:10 UTC

Major Market Movers

Bayer Shares Surge After Monsanto Appeal Win

5 mar 2024, 09:09 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bayer Decides Against Splitting Into Separate Units for Now -- 2nd Update

5 cze 2024, 09:57 UTC

Hot Stocks

Stocks to Watch Wednesday: CrowdStrike, HPE, Dollar Tree -- WSJ

14 maj 2024, 11:00 UTC

Market Talk
Earnings

Bayer Earnings Show Progression on Turnaround Strategy -- Market Talk

14 maj 2024, 05:34 UTC

Earnings

Bayer Backs 2024 Currency-Adjusted Outlook

14 maj 2024, 05:32 UTC

Earnings

Bayer: Analysts Saw 1Q Ebitda Before Special Items at EUR4.15B

14 maj 2024, 05:32 UTC

Earnings

Bayer 1Q Ebitda Before Special Items EUR4.41B

14 maj 2024, 05:32 UTC

Earnings

Bayer 1Q EPS EUR2.04

14 maj 2024, 05:32 UTC

Earnings

Bayer: Analysts Saw 1Q Sales at EUR14.08B

14 maj 2024, 05:32 UTC

Earnings

Bayer 1Q Sales EUR13.77B

14 maj 2024, 05:31 UTC

Earnings

Bayer 1Q EBIT EUR3.09B

14 maj 2024, 05:31 UTC

Earnings

Bayer: Analysts Saw 1Q Net Pft at EUR1.73B

14 maj 2024, 05:31 UTC

Earnings

Bayer 1Q Net Pft EUR2B

13 maj 2024, 13:26 UTC

Earnings

Bayer Investors Brace for Long Turnaround -- Talking Markets

15 kwi 2024, 14:01 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk

15 kwi 2024, 13:39 UTC

Market Talk

Bayer's Debt Reduction, Litigation and Drug Pipeline in Focus at 1Q Results -- Market Talk

22 mar 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ -2-

22 mar 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ

5 mar 2024, 10:23 UTC

Earnings

Bayer CEO Was Speaking on Call After Earnings

5 mar 2024, 10:19 UTC

Market Talk
Earnings

Bayer's EPS Guidance Implies Consensus Downgrades -- Market Talk

5 mar 2024, 09:55 UTC

Market Talk
Earnings

Bayer's 2024 Guidance Is Below Expectations -- Market Talk

5 mar 2024, 09:44 UTC

Earnings

Bayer CEO: Time it Takes For Major Structural Change is Time We Don't Have, Need to Focus on Challenges

5 mar 2024, 09:44 UTC

Earnings

Bayer CEO: There Has Been Calls From Major Shareholders For Break-Up, But They Understand Associated Drawbacks

5 mar 2024, 08:52 UTC

Earnings

Bayer CEO: Exploring All Avenues to Remove Litigation Completely

5 mar 2024, 08:51 UTC

Earnings

Bayer CEO: Strategy of Defence Against Litigation is Not Enough

5 mar 2024, 08:44 UTC

Earnings

Bayer CEO: Need Total Focus on Overcoming Challenges

5 mar 2024, 08:44 UTC

Earnings

Bayer CEO: Separation of Consumer Health Would Remove Steady Cash Flowing Business, Valutions Not Great

5 mar 2024, 08:43 UTC

Earnings

Bayer CEO: IPO or Spin Would Require All-Hands on Deck For Long Period

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

17.31% upside

12 Months Forecast

Average 30.5 EUR  17.31%

High 34 EUR

Low 28 EUR

Based on 12 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

12 ratings

1

Buy

11

Hold

0

Sell

Technical Score

By Trading Central

25.62 / 26.13Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

360 / 457 Ranking in Finance

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non